Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Juillerat

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Inflammatory Bowel Diseases|August 22, 2013
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitalsPascal Juillerat, Sharmeel K Wasan, Sharyle A Fowler, et al.
British Journal of Pharmacology|January 29, 2021
A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel diseaseFlorian Ruiz, Annika Wyss, Jean-Benoît Rossel, et al.
Journal of Crohn'S & Colitis|September 2, 2022
ECCO Topical Review: Roadmap to Optimal Peri-Operative Care in IBDShaji Sebastian, Jonathan P Segal, Charlotte Hedin, et al.
Nature Medicine|January 22, 2019
Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Nature Medicine|March 9, 2019
Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in SwitzerlandKathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, et al.
United European Gastroenterology Journal|July 19, 2019
Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the diseasePhilipp Schreiner, Bahtiyar Yilmaz, Jean-Benoît Rossel, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Inflammatory Bowel Diseases|August 22, 2013
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitalsPascal Juillerat, Sharmeel K Wasan, Sharyle A Fowler, et al.
British Journal of Pharmacology|January 29, 2021
A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel diseaseFlorian Ruiz, Annika Wyss, Jean-Benoît Rossel, et al.
Journal of Crohn'S & Colitis|September 2, 2022
ECCO Topical Review: Roadmap to Optimal Peri-Operative Care in IBDShaji Sebastian, Jonathan P Segal, Charlotte Hedin, et al.
Nature Medicine|January 22, 2019
Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Nature Medicine|March 9, 2019
Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in SwitzerlandKathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, et al.
United European Gastroenterology Journal|July 19, 2019
Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the diseasePhilipp Schreiner, Bahtiyar Yilmaz, Jean-Benoît Rossel, et al.
Pageof 11